Prevalence of comorbidity in patients with chronic obstructive pulmonary disease
Barra lateral del artículo
Publicado:
oct. 20, 2018
Palabras clave:
Enfermedad pulmonar obstructiva crónica, Comorbilidad, Calidad de vida, Estudios transversales
Contenido principal del artículo
Resumen
La comorbilidad es frecuente en pacientes con enfermedad pulmonar obstructiva crónica (EPOC); sin embargo, es inconsistente la relación entre la comorbilidad y la calidad de vida. El objetivo fue establecer la prevalencia de comorbilidad y la relación con la calidad de vida de los pacientes con EPOC en Santa Marta, Colombia. Se diseñó un estudio transversal en el que participaron pacientes ambulatorios con diagnóstico de EPOC. La calidad de vida se evaluó con el instrumento CAT (COPD Assessment Test), las puntuaciones mayores de diez se consideraron pobre calidad de vida. La muestra fue de 292 pacientes, en edades entre 49 y 95 años; 61,6% de sexo masculino. Un grupo de 232 participantes (79,5%) presentó alguna comorbilidad asociada a la EPOC. La calidad de vida fue pobre en 192 pacientes (65,8%). La comorbilidad no asoció significativamente a la calidad de vida (OR=1,33; IC95% 0,72-2,45), ajustado por edad y sexo. Se concluye que la comorbilidad es muy frecuente; no obstante, afecta poco la calidad de vida en pacientes con EPOC de Santa Marta. Se necesitan más investigaciones con mayor número de participantes.
Descargas
Los datos de descargas todavía no están disponibles.
Detalles del artículo
Cómo citar
Pedrozo-Pupo, J. C., Campo-Arias, A., & De La Torre, H. (2018). Prevalence of comorbidity in patients with chronic obstructive pulmonary disease. Duazary, 15(3), 273–280. https://doi.org/10.21676/2389783X.2418
Sección
Artículo de investigación científica y tecnológica
No se permite un uso comercial de la obra original ni de las posibles obras derivadas, la distribución de las cuales se debe hacer con una licencia igual a la que regula la obra original.
Citas
1. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008; 133 (2): 343-9. DOI 10.1378/chest.07-1361.
2. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006; 173 (12): 1390-413. DOI: 10.1164/rccm.200508-1211ST
3. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003; 56 (3): 221-9.
4. Bonavita V, De Simone R. Towards a definition of comorbidity in the light of clinical complexity. Neurol Sci. 2008; 29: 99-102. DOI 10.1007/s10072-008-0898-1
5. Dean E. Multiple morbidities assessment. Nurs Stand. 2017; 31 (34): 15. DOI 10.7748/ns.31.34.15.s16
6. Sin DD, Man SP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2 (1): 8-11. DOI 10.1513/pats.200404-032MS
7. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2): 155-161. DOI 10.1164/rccm.201201-0034OC
8. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013; 1(1):73-83. DOI 10.1016/S2213-2600(12)70060-7
9. Ardila R. Calidad de vida: una definición integradora. Rev Latinoam Psicol. 2003; 35 (2): 161-4.
10. Urzúa A, Caqueo-Urízar A. Calidad de vida: Una revisión teórica del concepto. Ter Psicol. 2012; 30: 61-71. DOI 10.4067/S0718-48082012000100006
11. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006; 119; 10 (Suppl. 1): 38-45. DOI 10.1016/j.amjmed.2006.08.006
12. Monteagudo M, Rodríguez-Blanco T, Llagostera M, Valero C, Bayona X, et al. Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. Respir Med. 2013; 107 (10): 1589-97. DOI 10.1016/j.rmed.2013.05.009
13. Pineda-Higuita SE, Ramos-Melchor VJ, Cadavid-Carmona D. Calidad de vida en pacientes con Enfermedad Pulmonar Obstructiva. Univ Salud. 2016; 18 (3): 482-93. DOI 10.22267/rus.161803.53
14. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax. 2008; 63 (6): 487-92. DOI 10.1136/thx.2007.086371
15. García-Olmos L, Alberquilla Á, Ayala V, García-Sagredo P, Morales L, Carmona M, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract. 2013; 14 (1): 11. DOI 10.1186/1471-2296-14-11
16. Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-morbidities and severity of COPD. COPD. 2015; 12 (4): 390-4. DOI 10.3109/15412555.2014.974734
17. Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001–2008. COPD. 2013; 10 (3): 324-32. DOI 10.3109/15412555.2012.744963
18. Koskela J, Kilpeläinen M, Kupiainen H, Mazur W, Sintonen H, Boezen M, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med. 2014; 14 (1): 102. DOI 10.1186/1471-2466-14-102
19. Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, et al. COPD comorbidities network. Eur Respir J. 2015; 46 (3): 640-50. DOI 10.1183/09031936.00171614
20. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid influences on generic health-related quality of life in COPD: a systematic review. PloS One. 2015; 10 (7): e0132670.DOI 10.1371/journal.pone.0132670
21. Katz MH. Multivariable analysis. Second edition. Cambridge: Cambridge University Press; 2006.
22. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017. Global strategy for the diagnosis, management and Prevent of chronic obstructive pulmonary disease, updated 2014. Disponible en: http://www.goldcopd.org (Fecha de acceso: 01-05-2017).
23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et, al. Standardisation of spirometry. Euro Respir J. 2005; 26 (2): 319-38. DOI 10.1183/09031936.05.00034805
24. Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, et al. Diagnosis of airway obstruction in the elderly: contribution of the SARA study. Inter J Chron Obstruct Pulmon Dis. 2012; 7: 389-95. DOI 10.2147/COPD.S31630
25. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34 (3): 648-54. DOI 10.1183/09031936.00102509
26. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014; 44 (4): 873-84. DOI 10.1183/09031936.00025214
27. IBM-SPSS Statistics for Windows, version 22.0. Armonk: SPSS. Inc.; 2013.
28. Resolución 008430 por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá: Ministerio de Salud de Colombia; 1993.
29. Mesa SB, Restrepo DA. Conceptos esenciales de la EPOC, prevalencia e impacto en América Latina. Medicina UPB. 2015; 34 (1):49-60.
30. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22 (130): 454-75. DOI 10.1183/09059180.00008612
31. van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J. 2005; 19(4): 326-34. DOI 10.4104/pcrj.2010.00053
32. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. J Fam Plann Reprod Health Care. 2008;34(4): 261-4.
33. Fosgate GT. Practical sample size calculations for surveillance and diagnostic investigations. J Vet Diag Invest. 2009; 21(1):3-14.
2. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006; 173 (12): 1390-413. DOI: 10.1164/rccm.200508-1211ST
3. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003; 56 (3): 221-9.
4. Bonavita V, De Simone R. Towards a definition of comorbidity in the light of clinical complexity. Neurol Sci. 2008; 29: 99-102. DOI 10.1007/s10072-008-0898-1
5. Dean E. Multiple morbidities assessment. Nurs Stand. 2017; 31 (34): 15. DOI 10.7748/ns.31.34.15.s16
6. Sin DD, Man SP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2 (1): 8-11. DOI 10.1513/pats.200404-032MS
7. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2): 155-161. DOI 10.1164/rccm.201201-0034OC
8. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013; 1(1):73-83. DOI 10.1016/S2213-2600(12)70060-7
9. Ardila R. Calidad de vida: una definición integradora. Rev Latinoam Psicol. 2003; 35 (2): 161-4.
10. Urzúa A, Caqueo-Urízar A. Calidad de vida: Una revisión teórica del concepto. Ter Psicol. 2012; 30: 61-71. DOI 10.4067/S0718-48082012000100006
11. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006; 119; 10 (Suppl. 1): 38-45. DOI 10.1016/j.amjmed.2006.08.006
12. Monteagudo M, Rodríguez-Blanco T, Llagostera M, Valero C, Bayona X, et al. Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. Respir Med. 2013; 107 (10): 1589-97. DOI 10.1016/j.rmed.2013.05.009
13. Pineda-Higuita SE, Ramos-Melchor VJ, Cadavid-Carmona D. Calidad de vida en pacientes con Enfermedad Pulmonar Obstructiva. Univ Salud. 2016; 18 (3): 482-93. DOI 10.22267/rus.161803.53
14. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax. 2008; 63 (6): 487-92. DOI 10.1136/thx.2007.086371
15. García-Olmos L, Alberquilla Á, Ayala V, García-Sagredo P, Morales L, Carmona M, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract. 2013; 14 (1): 11. DOI 10.1186/1471-2296-14-11
16. Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-morbidities and severity of COPD. COPD. 2015; 12 (4): 390-4. DOI 10.3109/15412555.2014.974734
17. Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001–2008. COPD. 2013; 10 (3): 324-32. DOI 10.3109/15412555.2012.744963
18. Koskela J, Kilpeläinen M, Kupiainen H, Mazur W, Sintonen H, Boezen M, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med. 2014; 14 (1): 102. DOI 10.1186/1471-2466-14-102
19. Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, et al. COPD comorbidities network. Eur Respir J. 2015; 46 (3): 640-50. DOI 10.1183/09031936.00171614
20. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid influences on generic health-related quality of life in COPD: a systematic review. PloS One. 2015; 10 (7): e0132670.DOI 10.1371/journal.pone.0132670
21. Katz MH. Multivariable analysis. Second edition. Cambridge: Cambridge University Press; 2006.
22. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017. Global strategy for the diagnosis, management and Prevent of chronic obstructive pulmonary disease, updated 2014. Disponible en: http://www.goldcopd.org (Fecha de acceso: 01-05-2017).
23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et, al. Standardisation of spirometry. Euro Respir J. 2005; 26 (2): 319-38. DOI 10.1183/09031936.05.00034805
24. Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, et al. Diagnosis of airway obstruction in the elderly: contribution of the SARA study. Inter J Chron Obstruct Pulmon Dis. 2012; 7: 389-95. DOI 10.2147/COPD.S31630
25. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34 (3): 648-54. DOI 10.1183/09031936.00102509
26. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014; 44 (4): 873-84. DOI 10.1183/09031936.00025214
27. IBM-SPSS Statistics for Windows, version 22.0. Armonk: SPSS. Inc.; 2013.
28. Resolución 008430 por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá: Ministerio de Salud de Colombia; 1993.
29. Mesa SB, Restrepo DA. Conceptos esenciales de la EPOC, prevalencia e impacto en América Latina. Medicina UPB. 2015; 34 (1):49-60.
30. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22 (130): 454-75. DOI 10.1183/09059180.00008612
31. van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J. 2005; 19(4): 326-34. DOI 10.4104/pcrj.2010.00053
32. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. J Fam Plann Reprod Health Care. 2008;34(4): 261-4.
33. Fosgate GT. Practical sample size calculations for surveillance and diagnostic investigations. J Vet Diag Invest. 2009; 21(1):3-14.